Aclaris Therapeutics (ACRS) Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ACRS Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Aclaris Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.53 |
| 52 Week High | US$5.15 |
| 52 Week Low | US$1.22 |
| Beta | 0.78 |
| 1 Month Change | 6.59% |
| 3 Month Change | 40.25% |
| 1 Year Change | 251.16% |
| 3 Year Change | -46.39% |
| 5 Year Change | -78.46% |
| Change since IPO | -59.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACRS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -11.0% | -0.1% | -0.3% |
| 1Y | 251.2% | 38.7% | 26.7% |
Return vs Industry: ACRS exceeded the US Pharmaceuticals industry which returned 36.1% over the past year.
Return vs Market: ACRS exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| ACRS volatility | |
|---|---|
| ACRS Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ACRS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACRS's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 71 | Neal Walker | www.aclaristx.com |
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Aclaris Therapeutics, Inc. Fundamentals Summary
| ACRS fundamental statistics | |
|---|---|
| Market cap | US$621.50m |
| Earnings (TTM) | -US$69.66m |
| Revenue (TTM) | US$8.37m |
Is ACRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACRS income statement (TTM) | |
|---|---|
| Revenue | US$8.37m |
| Cost of Revenue | US$64.27m |
| Gross Profit | -US$55.91m |
| Other Expenses | US$13.76m |
| Earnings | -US$69.66m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | -668.18% |
| Net Profit Margin | -832.58% |
| Debt/Equity Ratio | 0% |
How did ACRS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 10:57 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aclaris Therapeutics, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Donald Ellis | Citizens JMP Securities, LLC |
| Adam Vogel | Craig-Hallum Capital Group LLC |